A phase II study of non-platinum based chemotherapy with paclitaxel and vinorelbine in non-small cell lung cancer.

Abstract

INTRODUCTION Paclitaxel and vinorelbine combination in previous untreated patients with stage IIIb-IV non-small cell lung cancer (NSCLC) as a phase II study. PATIENTS AND METHODS Thirty-four patients (4 patients with stage IIIb, 30 patients in stage IV), with median age 66 and performance status 0-1, were administered paclitaxel, 175 mg/m(2) in a 3-h infusion rate on day 1 and vinorelbine, 25 mg/m(2) in a 10-min infusion rate on days 1, and 8 with G-CSF and EPO support. RESULTS Among our 33 evaluable patients for toxicity 16 patients (48.4%) presented leukopenia and 15 patients (45.4%) presented anemia despite G-CSF and EPO administration. Two patients (6%) presented Grade III-IV peripheral neuropathy. The overall response rate was 67.7%; 5 patients (16.1%) showed complete response (2 patients stage IIIb) and 16 patients (51.6%) showed partial response (1 patient stage IIIb). The overall median survival time was 10 months (range 3-18 months) and the median disease-free survival was 9 months (range 3-15 months) with an 1-year survival time of 45.1% (14 patients). CONCLUSION The results of the combination as 1st line treatment for patients with non-operable NSCLC are promising and should be further investigated.

Statistics

050100'04'05'06'07'08'09'10'11'12'13'14'15'16'17
Citations per Year

64 Citations

Semantic Scholar estimates that this publication has 64 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Ginopoulos2002API, title={A phase II study of non-platinum based chemotherapy with paclitaxel and vinorelbine in non-small cell lung cancer.}, author={Panagiotis V. Ginopoulos and Emanuel Kontomanolis and Dimitrios M. Kardamakis and Maria Sougleri and Spiros Rathosis and Afroditi Karana and Helias Christias and George J. Mandellos}, journal={Lung cancer}, year={2002}, volume={38 2}, pages={199-203} }